Welcome to our dedicated page for Arcus Biosciences SEC filings (Ticker: RCUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcus Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company whose common stock trades on the New York Stock Exchange under RCUS. Form 8-K reports include quarterly and annual results furnished with pipeline updates, clinical program disclosures, collaboration updates, executive changes and material agreements tied to the company’s financing and development activities.
Arcus filings also cover capital structure and governance matters, including a completed common stock offering, amendments to a loan and security agreement, annual proxy materials, board and executive compensation disclosures, equity incentive matters and stockholder meeting proposals. The filing record reflects risk and operating disclosures connected to drug development, clinical studies, regulatory pathways, collaborations and funding needs.
Arcus Biosciences Inc. has a notice of proposed sale under Rule 144 for 6,552 shares of common stock, to be sold through Merrill Lynch on the NYSE around 12/31/2025, with an aggregate market value of $153,185.76. Common shares outstanding were 107,973,536.
The seller, Robert C. Goeltz II, acquired these 6,552 shares on 12/15/2025 as a restricted stock unit grant from Arcus Biosciences, recorded as equity compensation. Over the prior three months, he reported multiple sales of common stock: 5,000 shares on 10/28/2025 for $100,000, 5,000 shares on 11/26/2025 for $125,000, 6,702 shares on 12/16/2025 for $146,668.58, and 5,960 shares on 12/17/2025 for $132,070.62.
Arcus Biosciences, Inc. reported that its general counsel sold company stock in mid-December 2025 in transactions related to restricted stock unit (RSU) vesting. On December 16, 2025, 7,658 shares of common stock were sold at a weighted average price of $21.8843, leaving 131,544 shares beneficially owned afterward. On December 17, 2025, a further 6,810 shares were sold at a weighted average price of $22.1595, resulting in 124,734 shares beneficially owned. The filing explains that these sales were made by the issuer on the reporting person’s behalf to cover tax withholding obligations triggered by RSU vesting under an equity administration policy implemented on May 22, 2025, and are described as non‑discretionary trades. The remaining holdings include one share acquired through the company’s employee stock purchase plan and the unvested portion of the reporting person’s RSU grants.
Arcus Biosciences Chief Medical Officer reports automatic share sales and corrects equity award vesting terms. On 12/16/2025 and 12/17/2025, the CMO sold 5,052 and 4,494 shares of common stock, respectively, as reported sales to cover tax withholding obligations tied to vesting restricted stock units. The filing states these sales occurred automatically under the company’s equity administration policy and were not discretionary trades. After these transactions, the CMO beneficially owned 70,141 and then 65,647 shares, including unvested RSUs. The document also corrects the vesting schedule for awards granted on February 10, 2025: RSUs vest in four equal annual installments beginning December 15, 2025, and stock options become exercisable in 48 equal monthly installments after January 31, 2025, subject to continued service.
Arcus Biosciences’ Chief Accounting Officer reported routine stock sales over three days in December 2025. On December 16, 17, and 18, 2025, the officer reported selling 2,376, 2,113, and 4,343 shares of common stock, respectively, at weighted average prices of $21.8843, $22.1595, and $22.2458 per share.
According to the footnotes, the first two sales were made by the issuer on the officer’s behalf to cover tax withholding obligations from vesting restricted stock units and occurred automatically under the company’s equity administration policy implemented on May 22, 2025. The sales on December 18, 2025 were effected under a Rule 10b5-1 trading plan adopted on June 6, 2025. After these transactions, the officer beneficially owned 18,531 shares, including unvested RSUs.
Arcus Biosciences, Inc. reported insider share sales by its Chief Financial Officer related to restricted stock unit (RSU) vesting. On 12/16/2025, the CFO sold 6,702 shares of common stock at a weighted average price of $21.8843 per share, and on 12/17/2025, sold an additional 5,960 shares at a weighted average price of $22.1595 per share.
The company states these shares were sold by the issuer on the CFO’s behalf to cover tax withholding obligations arising from the vesting of previously granted RSUs, under an equity administration policy implemented on May 22, 2025, and that the sales were not discretionary trades. Following these transactions, the CFO beneficially owned 80,436 shares after the first sale and 74,476 shares after the second sale, which include the unvested portion of her RSU grants.
Arcus Biosciences, Inc. reported that its Chief Operating Officer, a company officer, sold shares of common stock in mid-December 2025 in connection with restricted stock unit (RSU) vesting. On 12/16/2025, 11,225 shares were sold at a weighted average price of $21.8843, leaving 203,007 shares beneficially owned. On 12/17/2025, 9,983 shares were sold at a weighted average price of $22.1595, leaving 193,024 shares beneficially owned.
The filing explains that these sales were made by the issuer on the officer’s behalf solely to cover tax withholding obligations tied to the vesting of previously granted RSUs, and occurred automatically under the company’s equity administration policy rather than as discretionary trades. The remaining beneficial ownership figure includes unvested portions of the officer’s RSU grants.
Arcus Biosciences’ president reports automatic tax‑related share sales tied to RSU vesting. On 12/16/2025 and 12/17/2025, the reporting officer sold 11,225 and 9,983 shares of Arcus Biosciences common stock, respectively, at weighted average prices of $21.8843 and $22.1595 per share. The filing explains these sales were made by the company on the officer’s behalf to cover tax withholding obligations when certain previously granted restricted stock units vested, under an equity administration policy implemented on May 22, 2025, and were not discretionary trades. After these transactions, the officer beneficially owns 346,012 shares directly, including unvested RSUs, and 954,063 shares indirectly through a trust.
Arcus Biosciences, Inc. Chief Executive Officer and director reported automatic sales of company stock mainly to cover taxes tied to equity awards. On 12/16/2025, 28,947 shares of common stock were sold at a weighted average price of $21.8843, and on 12/17/2025, 25,744 shares were sold at a weighted average price of $22.1595, both coded as open-market sales. According to the footnotes, these transactions were carried out by the issuer on the executive’s behalf to satisfy tax withholding obligations upon the vesting of previously granted restricted stock units and were not discretionary trades by the executive.
After these transactions, the reporting person beneficially owned 2,194,809 shares of Arcus Biosciences common stock, which includes 236 shares acquired on November 30, 2025 through the company’s employee stock purchase plan and the unvested portion of outstanding RSU grants.
A shareholder of RCUS, Alexander Azoy, plans to sell 4,343 shares of common stock through Morgan Stanley Smith Barney on or about 12/18/2025 on the NYSE, with an aggregate market value of $96,762.04, compared with 107,973,536 shares outstanding.
The shares to be sold were acquired from the issuer on 12/15/2025 as restricted stock units. The notice also lists recent Rule 10b5-1 sales in the past three months, including 1,900 shares sold on 11/26/2025 for $49,400 and 2,831 shares sold on 09/29/2025 for $36,803.
Arcus Biosciences, Inc. amended its loan agreement with Hercules Capital and other lenders to modify access to the remaining $150.0 million of term loan commitments and extend the debt maturity date to September 1, 2030. The amendment makes $25.0 million available at the company’s option through March 15, 2026 and another $25.0 million available through September 15, 2026. A further up to $50.0 million becomes available after a specified Phase 3 clinical data milestone that supports a U.S. FDA Biologics License Application or New Drug Application, and an additional up to $50.0 million becomes available after FDA approval of such an application, each within defined time windows.
If the aggregate outstanding principal of the term loans exceeds $200.0 million, starting with financials for the third quarter after FDA approval, Arcus must meet new performance covenants based on market capitalization, levels of “Qualified Cash,” or certain net product revenue thresholds.